{"organizations": [], "uuid": "35d971aa64fe46bdf3cade1e6351ff68804682b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-beigene-and-boehringer-ingelheim-a/brief-beigene-and-boehringer-ingelheim-announce-commercial-supply-agreement-for-tislelizumab-idUSASB0C0E3", "country": "US", "domain_rank": 408, "title": "BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T16:20:00.000+02:00", "replies_count": 0, "uuid": "35d971aa64fe46bdf3cade1e6351ff68804682b3"}, "author": "", "url": "https://www.reuters.com/article/brief-beigene-and-boehringer-ingelheim-a/brief-beigene-and-boehringer-ingelheim-announce-commercial-supply-agreement-for-tislelizumab-idUSASB0C0E3", "ord_in_thread": 0, "title": "BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab", "locations": [], "entities": {"persons": [{"name": "boehringer", "sentiment": "none"}], "locations": [], "organizations": [{"name": "boehringer ingelheim announce co", "sentiment": "negative"}, {"name": "beigene ltd", "sentiment": "none"}, {"name": "tislelizumab reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 9, 2018 / 2:20 PM / Updated 6 minutes ago BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab Reuters Staff \nJan 9 (Reuters) - Beigene Ltd: \n* BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB \n* BEIGENE LTD - BOEHRINGER INGELHEIM WILL MANUFACTURE TISLELIZUMAB IN CHINA UNDER AN EXCLUSIVE MULTI-YEAR ARRANGEMENT, WITH CONTRACT EXTENSION POSSIBLE \n* BEIGENE LTD - CO ALSO OBTAINED CERTAIN PREFERRED RIGHTS FOR FUTURE CAPACITY EXPANSION BY BOEHRINGER INGELHEIM IN CHINA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-09T16:20:00.000+02:00", "crawled": "2018-01-09T16:33:12.002+02:00", "highlightTitle": ""}